Business Wire

ESI-GROUP

21.10.2021 08:02:16 CEST | Business Wire | Press release

Share
Gaïa Rating - New Award for ESI Group's ESG Commitment

Regulatory News:

Gaïa Research, a service of EthiFinance and a major player in the field of ESG rating (environment, social and governance) of French mid-sized listed companies, has awarded ESI Group (Paris:ESI), a global player in virtual prototyping, committed to a cleaner, safer, and more productive industry, the first Gaïa 2021 prize in the category of mid-cap companies with annual revenues under €150 million.

This award received during the ceremony held on October 19th , 2021 in Paris, illustrates the efforts made by the Group to continuously improve its CSR commitments (social, societal, and environmental).

2021 was shaped by several significant actions for ESI Group, both within its governance, its environmental commitments, some in collaboration with Reforest'Action , and above all, with initiatives dedicated to its employees.

Particularly shaken by the Covid-19 health crisis, the work-life balance was a field of action for ESI Group, which employs 1,200 people in about 20 countries. In this context, the Group has introduced a "No-Meeting Day ": one-day per week dedicated to restoring the importance of taking time, without meetings, enabling employees to work differently. While reducing the stress and pressure caused by overloaded agendas, this format increases the concentration and productivity of teams.

"We are delighted with this new distinction from Gaïa Research. In 2021, ESI succeeded in optimizing its ESG commitment on all areas. The pandemic has disrupted the lives of our teams as well as our work habits. With the ‘No-Meeting Day’, we wanted to offer an initiative that would give our employees the opportunity to break the rhythm which could sometimes be counterproductive and allow them to thrive in their missions. We also worked for the Planet by helping reforestation, strengthened the independence of our governance and contributed to the decarbonization of the industry through our solutions. All this would not have been possible without the contribution of all our teams, who, in addition to being expert and recognized, reflect diversity. This is a real source of pride for all of us!" declared Corinne Romefort-Régnier , ESI Group's Governance Director.

“We want to be a vector of progress. The companies monitored by the Gaïa Research teams are growing companies with strong development ambitions. Our objective, in addition to supporting financial players in their responsible investment approach, is also to prepare companies for the new expectations of their stakeholders in terms of environmental, social and governance issues," says Emmanuel de La Ville of Gaïa Research. "Our evaluations allow investors to identify the most transparent and efficient companies in terms of CSR."

Methodology:
Since 2009, Gaïa Research has been conducting an annual data collection campaign covering most of the SMEs listed in France. Based on this information, companies are rated on their level of transparency and performance. The ratings are based on 174 criteria (economic, governance, human capital, environment and stakeholders) and are used by leading management companies in their management process and investment decisions. Since its creation, this index has outperformed the CAC 40 and the CAC Mid & Small every year.

About ESI Group
Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time, while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval, energy and heavy industry, ESI is present in more than 20 countries, employs 1200 people around the world and reported 2020 sales of €132.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.

For further information, go to www.esi-group.com .

Follow ESI
LinkedIn | Facebook | Twitter | YouTube

About Gaia Research, EthiFinance and Qivalio
Gaia Research is an EthiFinance service, a subsidiary of Qivalio, a European rating, research and consulting group dedicated to sustainable finance and development. The Group provides solutions to investors, companies and organizations to meet the challenges of financing and environmental and societal transformations. Created in 2017, Qivalio is the result of the merger between Spread Research and EthiFinance, French financial and extra-financial rating agencies founded in 2004. The group's purpose is to work towards the transformation of finance and the real economy for a more sustainable society, by promoting enlightened and responsible decision-making.

Qivalio serves a portfolio of leading international clients under Spread Research (independent credit research), Qivalio Ratings (financial rating agency), Qivalio Analytics (risk modelling) and EthiFinance (extra-financial rating and advisory agency) brands.

For further information: www.ethifinance.com www.qivalio.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye